Gap junction protein inhibitor, Gap 26, Purity ≥98%

Synonym: 197250-15-0; Gap-26; Gap26; (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-Amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid

MDL: MFCD06411601
CAS Number: 197250-15-0
Compound CID: 25088334

Product Size

5 mg; 10 mg; 25 mg; 50 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

Gap 26, soluble in DMSO, water and ethanol, is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting gap junction protein.

Molecular Weight

1550.78

Molecular Formula

C₇₀H₁₀₇N₁₉O₁₉S

Form

Lyophilized powder

Purity

≥98%

Titer

Free from inappropriate visible particulates, foreign matter, discoloration, or other defects

Solubility

In vitro: DMSO: 93 mg/mL (59.97 mM); Water: 93 mg/mL (59.97 mM); Ethanol: 47 mg/mL

Stability

In its lyophilized form, the chemical remains stable for 36 months.

Quality Level

Research grade

Applications

Gap 26 is a cytoskeletal signaling inhibitor that can be studied extensively for its potential therapeutic applications in the treatment of conditions involving altered gap junction communication, such as cancer and cardiovascular diseases.

Storage

Store at -20ºC, and keep desiccated.